Verici Dx Regulatory News (VRCI)

Verici Dx plc

("Verici Dx" or the "Company")

CEO Video Interview

Outlining positive data from Tuteva™ clinical validation study

Test performance better than existing care "by multiple times"

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that an interview with Chief Executive, Sara Barrington, has been published this morning highlighting the positive performance data for Tuteva™, the Company's post-transplant blood test focused on acute rejection. The interview can be viewed here:

https://www.voxmarkets.co.uk/articles/verici-dx-interview-with-ceo-sara-barrington-c2bbfd2/

In the interview, Sara highlights that the data from its blinded, international, multi-centre validation study shows the superior clinical performance of Tuteva™ compared to existing diagnostics "by multiple times" and that the data received a very positive response at the American Transplant Congress ("ATC") earlier this month.

The interview follows on from the news announced yesterday of further data demonstrating the effectiveness of the test in providing clinicians with actionable information to better inform the medical management of kidney transplant patients. Yesterday's announcement can be seen here: https://vericidx.com/tuteva-clinical-validation-study/

The positive performance data establishes a new industry standard in detection of acute kidney transplant rejection and paves way for US commercial launch in 2022.

The headline result from the study was originally announced on 12 May, which can be seen here: https://vericidx.com/positive-results-for-tuteva/

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.